Synbio International Inc.

Synbio International Inc.

OOTC:SYIN
0.00
USD
+0.00
(-33.33%)
0.00EPS
2.09MMarket Cap
Synbio International Inc.
OTC:SYIN
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Business
Synbio International, Inc. is a biotechnology company focused on synthetic biology solutions and related life sciences applications, with operations spanning multiple regions. Founded in 2001 and headquartered in Paris, Île-de-France, FR, the company develops and commercializes engineered biological products and services for healthcare, agriculture, and industrial applications, emphasizing biologically derived components, bioprocess technologies, and related support services. Main products and services: - Core biotech platforms: synthetic biology design/build, strain engineering, and optimization services; proprietary biological parts, devices, and systems for development and scale-up; post-production processing including purification and formulation of biological products. - Therapeutic and health-related solutions: engineered probiotic strains, postbiotic formulations, and biopharmaceutical development services; collaboration on biologics discovery, development, and manufacturing support; regulatory and quality assurance consulting tied to biologics programs. - Industrial and agricultural applications: bio-based chemicals, enzyme development, and fermentation workflows; plant and animal health products leveraging engineered microbes; environmental biotech solutions for waste processing and remediation. - Manufacturing and CDMO capabilities: contract development and manufacturing organization services for biotech products; process development, scale-up, analytical method development, and regulatory documentation support; supply chain and GMP-compliant production facilities. - Data, analytics, and advisory: genomic design data, simulation and modeling services, and technical due diligence for partner programs; regulatory pathway guidance and commercialization planning for biotech assets. Latest major company changes: - Strategic partnerships and collaborations: enters co-development agreements with biotech and pharmaceutical partners to advance engineered biologics and probiotic/ postbiotic products; expands alliance network to accelerate product commercialization. - Funding and corporate actions: completes or engages in funding rounds to support platform expansion and pipeline development; participates in acquisitions or restructurings to broaden capabilities in synthetic biology, fermentation, and downstream processing. - Product launches and service expansions: introduces new postbiotic and probiotic product lines under refined branding; launches enhanced CDMO services and scalable manufacturing processes for biotech assets. - Strategic shifts and geographic expansion: broadens international footprint, including expanded operations and collaborations in Europe and Asia; reinforces go-to-market strategy for global customers across healthcare, nutrition, and industrial biotech sectors. - Corporate reorganizations: undergoes organizational realignments to streamline R&D, manufacturing, and commercial functions; updates branding and product naming to reflect expanded capabilities. Additional context: - Industry and segments: biotechnology; synthetic biology; life sciences tools and solutions; probiotic and postbiotic research; bioprocess development and manufacturing; bio-based product commercialization. - Markets and customers: pharmaceutical and biotech developers, healthcare providers, food and beverage and nutraceutical manufacturers, agricultural and environmental biotech customers, and research institutions. - Geographic operations: headquarters in France with international activity across Europe and Asia; established collaborations and customer engagements in multiple regions, supported by global partners and distributors. - Subsidiaries and parent relationships: operates within a network of affiliates and partner organizations to deliver end-to-end biotech solutions; maintains strategic alliances that augment its platform capabilities.

Company News

  • Synbio (OTC: SYIN) Outlines a Two-Engine Healthcare Growth Strategy Combining Nutraceuticals and AI-Powered Mental Health Screening

  • Synbio International Signs Exclusive Licensing Agreement for Proprietary Nutraceutical Products, Accelerating Path to Revenue

  • Synbio International Commences Revenue-Generating Operations With Launch of Healing Force™ Nutraceutical Division

  • Synbio International Secures DWAC and DRS Eligibility

  • Synbio Signs Agreement for a Proof-of-Concept Clinical Trial to Evaluate a Unique AI-Based Facial Analysis Screening Software for Mental Health Disorders

  • Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

  • Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

  • Synbio International Inc. Strengthens Strategic Alliance with FacialDx Inc. through Share Purchase and Warrant Agreements

  • NATURAL HARMONY FOODS INC. COMPLETES FINANCIAL AUDITS FOR 2022 & 2023

  • Natural Harmony Foods Inc. Completes Financial Audits for 2022 & 2023

  • Reduction of Outstanding Common Stock

  • NATURAL HARMONY FOODS INC. CHANGING NAME AND LOGO TO BETTER REFLECT ITS NEW STRATEGIC DIRECTION

  • Natural Harmony Foods Inc. Changing Name and Logo to Better Reflect Its New Strategic Direction

  • NATURAL HARMONY FOODS INC. SIGNS US$5,000,000 EQUITY FACILITY TO FUND GROWTH

  • NATURAL HARMONY FOODS INC. ANNOUNCES NEW STRATEGIC DIRECTION AND SETS THE STAGE FOR A REVOLUTION IN HEALTHCARE AND WELLNESS